Recent advances in heart failure therapy include a variety of mechanical and device-based technologies that target structural aspects of heart failure that cannot be treated with drug therapy alone; these newer therapies can collectively be described as interventional heart failure therapy. This article is the second in a 2-part series reviewing interventional heart failure therapy. Interventions included in this discussion include those indicated for the treatment of end-stage refractory heart failure, including interventional medical therapy, interventional treatment of valvular disease, mechanical assist devices, and heart transplantation. Also included is a review of the currently available catheter-based pumps, which are intended to provide temporary support in patients with acute hemodynamic compromise. The use of cellular or stem cell therapy for the treatment of heart failure is an emerging interventional therapy and data supporting its use for the treatment heart failure will also be presented, as will a discussion of the role of palliative care and self-care in heart failure therapy.
Mancini D., Burkhoff D.Mechanical device-based methods of managing and treating heart failure. Circulation. 2005;112(3): 438-448.
2.
Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21-e181.
3.
Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation . N Engl J Med. 2007;357(9):885-896.
4.
Jessup M., Abraham W., Casey DE, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society of Heart and Lung Transplantation. Circulation. 2009;119(14):1977-2016.
5.
DiBianco R., Shabetai R., Kostuk W., Moran J., Schlant RC, Wright R.A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989;320(11):677-683.
6.
Dobbs SM, Kenyon WI, Dobbs RJMaintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. Br Med J. 1977;1(6063):749-752.
7.
Lee DC, Johnson RA, Bingham JB, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med. 1982;306(12):699-705.
8.
Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol. 1988;61(4): 371-375.
9.
O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J.1999;138(1 pt 1):78-86.
10.
Elkayam U., Tasissa G., Binanay C., et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153(1):98-104.
11.
Brozena S., Twomey C., Goldberg LR, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant. 2004;23(9):1082-1086.
12.
Upadya S., Lee FA, Saldarriaga C., et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. J Heart Lung Transplant. 2004; 23(4):466-472.
13.
Jimenez J., Jara J., Bednar B., Bauerlein J., Mallon S.Long-term (>8 weeks) home inotropic therapy as destination therapy in patients with advanced heart failure or as bridge to heart transplantation . Int J Cardiol. 2005;99(1):47-50.
14.
Moulpoulos SD, Topaz S., Kolff WJDiastolic balloon pumping (with carbon dioxide) in the aorta-a mechanical assistance to the failing circulation. Am Heart J. 1962;63:669-675.
15.
Mueller H., Ayres SM, Conklin EF, et al. The effects of intraaortic counterpulsation on cardiac performance and metabolism shock associated with acute myocardial infarction. J Clin Invest. 1971;50(9):1887-1900.
16.
Ferguson JJ , Cohen M., Freedman RJ, et al. The current practice of intra-aortic balloon counterpulsation: Results from the Benchmark Registry. J Am Coll Cardiol. 2001;38(5):1456-1462.
17.
Antman EM, Anobe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patents with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines . Circulation. 2004;110(5):558-636.
18.
Greenberg B. , Czerska B., Delgado RM, et al. Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the multicenter trial of the Orqis Medical Cancion System for the enhanced treatment of heart failure unresponsive to medical therapy (MOMENTUM). Circulation. 2008 ;118(12):1241-1249.
19.
Meyns B., Dens J., Sergeant P., Herijers P., Daenen W., Flameng W.Initial experiences with the Impella device in patients with cardiogenic shock . Thorac Cardiovasc Surg. 2003;51(6):312-317.
20.
Seyfarth M. , Sibbing D., Bauer I., et al. A randomized clinical trial to evaluate the savety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584-1588.
21.
Burkhoff D. , Cohen H., Brunckhorst C., O’Neill WWA randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. 2006;152(3): 469.e1-e8.
22.
Thiele H., Sick P., Boudriot E., et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005;26(13):1276-1283.
23.
Barbone A., Holmes JW, Heerdt PM, et al. Comparison of right and left ventricular assist device support in patients with severe heart failure: a primary role of mechanical unloading underlying reverse remodeling. Circulation. 2001;104(6):670-675.
24.
Zafeiridis A. , Jeevanandam V., Houser SR, Margulies KBRegression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998;98(7):656-662.
25.
Blaxall BC, Tschannen-Moran BM, Milano CA, Koch WJDifferential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol.2003;41(7):1096-1106.
26.
Bartling B., Milting H., Schumann H., et al. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation. 1999;100(19 suppl):11216-11223.
27.
Heerdt PM, Holmes JW, Cai B., et al. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure . Circulation. 2000;102(22):2713-2719.
28.
Ogletree-Hughes ML, Stull LB, Sweet WE, Smedira NG, McCarthy PM, Moravec CSMechanical unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in the failing human heart . Circulation. 2001;104(8):881-886.
29.
Terracciano CM, Harding SE, Adamson D., et al. Changes in sarcolemmal Ca Entry and sarcoplasmic reticulum Ca content in ventricular myocytes from patients with end-stage heart failure following myocardial recovery after combined pharmacological and ventricular assist device therapy. Eur Heart J. 2003;24(14):1329-1339.
30.
Terracciano CM, Hardy J., Birks EJ, Khaghani A., Banner NR, Yacoub MHClinical recovery from end-stage heart failure using left-ventricular assist devices and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation. 2004 ; 109(19):2263-2265.
31.
Chaudhary KW , Rossman EI, Piacentino V. 3rd, et al. Altered myocardial Ca2+ cycling after left ventricular assist device support in the failing human heart. J Am Coll Cardiol. 2004;44(4):837-845.
32.
Li YY, Feng Y., McTiernan CF, et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation. 2001;104(10):1147-1152.
33.
Dipla K., Mattiello JA, Jeevanandam V., Houser SR, Margulies KBMyocycte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998;97(23):2316-2322.
34.
Bruckner BA , Stetson SJ, Perez-Verdia A., et al. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J Heart Lung Transplant.2001; 20(4):457-464.
35.
Körfer R., El-Banayosy A., Arusoglu L., et al. Single-center experience with the thoratec ventricular assist device. J Thorac Cardiovasc Surg . 2000;119(3):596-600.
36.
Slaughter MS , Tsui SS, El-Banayosy A., et al. Results of a multicenter clinical trial with the Thoratec Implantable Ventricular Assist Device. J Thorac Cardiovasc Surg. 2007;133(6): 1573-1580.
37.
McBride LR, Naunheim KS, Fiore AC, Moroney DA, Swartz MTClinical experience with 111 Thoratec Ventricular Assist Devices. Ann Thorac Surg. 1999;67(5):1233-1238.
38.
Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443.
39.
Bank AJ, Mir SH, Nguyen DQ, et al. Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. Ann Thorac Surg. 2000;69(5):1369-1374.
Pagani FD, Miller LW, Russell SD, et al, for the HeartMate II Investigators.Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol.2009;54(4):312-321.
42.
Slaughter MS , Rogers JG, Milano CA, et al, and the HeartMate II Investigators.Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med.2009;361(23): 2241-2251.
43.
Copeland JG , Smith RG, Arabia FA, et al. Cardiac replacment with a total artificial heart as a bridge to transplantation. N Engl J Med. 2004;351(9):859-867.
44.
Kloner RA, Reffelmann T.Cellular cardiomyoplastycardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure?Cardiovasc Res.2003;58(2):358-368.
45.
Skobel E., Schuh A., Schwarz ER, et al. Transplantation of fetal cardiomyocytes into infracted rat hearts results in long-term functional improvement. Tissue Eng. 2004;10(5-6):849-864.
46.
Müller-Ehmsen J., Peterson KL, Kedes L., et al. Rebuilding a damaged heart: long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function. Circulation. 2002;105(14):1720-1726.
47.
Scorsin M., Hagege AA, Marotte F., et al. Does transplantation of cardiomyocytes improve function of infarcted myocardium?Circulation. 1997;96(9 suppl):11188-11193.
48.
Ince H., Petzsch M., Rehders TC, Chatterjee T., Nienaber CATranscatheter transplantation of autologous skeletal myoblasts in postinfarction patients with severe left ventricular dysfunction. J Endovasc Ther. 2004;11(6):695-704.
49.
Smits PC, van Geuns RJ, Poldermans D., et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol. 2003;42(12): 2063-2069.
50.
Menasche P. , Alfieri O., Janssens S., et al. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial. Circulation. 2008;117(9):1189-200.
51.
Dawn B., Bolli R.Adult bone marrow-derived dells: regenerative potential, plasticity, and tissue commitment. Basic Res Cardiol. 2005;100(6):494-503.
52.
Abdel-Latif A., Bolli R., Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med.2007;167(10):989-997.
53.
Smith RR, Barile L., Cho HC, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation . 2007;115(7): 896-908.
54.
Smith RR, Barile L., Messina E., Marban E. Stem cells in the heart: what’s the buzz all about?-Part 1: preclinical considerations. Heart Rhythm. 2008;5(5):749-757.
55.
Joggerst SJ, Antonis K.Hatzopoulos stem cell therapy for cardiac repair: benefits and barriers. Expert Rev Mol Med. 2009;11:e20.
56.
Menasché P.Stem cell therapy for heart failure: are arrhythmias a real safety concern?Circulation. 2009;119(20):2735-2740.
57.
Goodlin SJPalliative care in congestive heart failure. J Am Coll Cardiol . 2009;54(5):386-396.
58.
Riegel B., Carlson B., Moser DK, Sebern M., Hicks FD, Roland V.Psychometric testing of the self-care of heart failure index. J Card Fail. 2004;10(4):350-360.
59.
Riegel B., Moser DK, Anker SD, et al. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation. 2009; 120(12):1141-1163.
60.
Woodend AK, Sherrard H., Fraser M., Stuewe L., Cheung T., Struthers C.Telehome monitoring in patients with cardiac disease who are at high risk of readmission. Heart Lung. 2008;37(1):36-45.
61.
Dansky KH, Vasey J., Bowles K.Impact of telehealth on clinical outcomes in patients with heart failure. Clin Nurs Res. 2008; 17(3):182-199.
62.
Maric B., Kaan A., Ignaszewski A., Lear SAA systematic review of telemonitoring technologies in heart failure. Eur J Heart Fail. 2009;11(5):506-517.
63.
Catanzariti D., Lunati M., Landolina M., et al, for the Italian Clinical Service Optivol-CRT Group.Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. Pacing Clin Electrophysiol.2009;32(3):363-370.
64.
Yu CM, Wang L., Chau E., et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization . Circulation. 2005;112(6):841-848.
65.
Bourge RC, Abraham WT, Adamson PB, et al, for the COMPASS-HF Study Group.Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol.2008;51(11):1073-1079.
